{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:09:55Z","timestamp":1774368595907,"version":"3.50.1"},"reference-count":49,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100032626","name":"Unitaid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite the availability of curative treatments, hepatitis C diagnosis and treatment coverage is suboptimal globally with few countries on track to achieve the WHO\u2019s 2030 elimination targets. In 2022, an estimated 50 million people were living with hepatitis C, with 1 million new infections annually. Most people living with hepatitis C reside in low- and middle-income countries, and people who inject drugs are disproportionately affected by hepatitis C.<\/jats:p>\n                    <jats:p>Continuing simplification of diagnostic pathways and treatment care models is required to improve linkage to care and reduce costs associated with hepatitis C treatment and cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is a multi-country non-randomised, quasi-experimental, prospective comparative two-arm trial. It aims to assess the feasibility of implementation, retention in hepatitis C care and achievement of cure and cost-effectiveness outcomes, comparing two simplified hepatitis C testing and treatment pathways.<\/jats:p>\n                    <jats:p>Arm 1 is a standard simplified test and treat model of care following global guidance, and arm 2 is an innovative rapid, same-day treatment initiation model of care using a presumptive treatment approach based on shortened read-time of the point-of-care OraQuick hepatitis C antibody test result. Secondary outcomes include assessing the accuracy of the OraQuick hepatitis C antibody test in predicting viraemia and the acceptability of each pathway.<\/jats:p>\n                    <jats:p>This study will be implemented in Armenia, Georgia and Tanzania. Treatment-na\u00efve people who inject drugs aged over 18 years in each country will be eligible for enrolment.<\/jats:p>\n                    <jats:p>Recruitment commenced in October 2024 in Armenia, June 2025 in Georgia and August 2025 in Tanzania and is anticipated to close by December 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This trial has been reviewed by WHO Ethics Review Committee (ERC), Alfred Hospital Ethics Committee (Australia) and local country ERCs. Alongside journal publications and conferences, the results from this study will be disseminated through summary reports and workshops with key stakeholders and with communities of people affected by HCV through relevant organisations\/networks, including the global Community Advisory Board (CAB). The study results will inform national scale-up of simplified care models and inform potential pathways for further simplification of care models, including the potential for one-step diagnostic pathways and same-day treatment in particular scenarios for the three study countries, and other low- and middle-income countries globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06159504\">NCT06159504<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-114119","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:30:01Z","timestamp":1774366201000},"page":"e114119","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06159504","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-2510","authenticated-orcid":false,"given":"Bridget Louise","family":"Draper","sequence":"first","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9199-5463","authenticated-orcid":false,"given":"Mia","family":"Flynn","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Wisse","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith","family":"Aikaeli","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zin Mar","family":"Han","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Ayako","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Bajis","sequence":"additional","affiliation":[{"name":"Department of Global HIV, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Butsashvili","sequence":"additional","affiliation":[{"name":"Georgia Health Research Union, Tbilisi, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamo","family":"Davtyan","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tea","family":"Kordzadze","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Lamand","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Luhmann","sequence":"additional","affiliation":[{"name":"Department of Global HIV, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knarik","family":"Sargsyan","sequence":"additional","affiliation":[{"name":"M\u00e9decins du Monde, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mbazi","family":"Senkoro","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research, Dar es Salaam, United Republic of Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Scott","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Stone","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Voloshin","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Walker","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Madden","sequence":"additional","affiliation":[{"name":"International Network of People who Use Drugs (INPUD), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Stoov\u00e9","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"},{"name":"La Trobe University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"},{"name":"Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"The University of Melbourne School of Population and Global Health, Melbourne, Victoria, Australia"},{"name":"Doherty Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1998-5722","authenticated-orcid":false,"given":"Alisa","family":"Pedrana","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026032408151697000_16.3.e114119.1","unstructured":"Geneva, Global HIV HaSPH, Health Product Policy and Standards (HPS) . Global hepatitis report 2024: action for access in low- and middle-income countries. 2024."},{"key":"2026032408151697000_16.3.e114119.2","unstructured":"Geneva, Global HIV HaSPH, Health Product Policy and Standards (HPS) . Accelerating access to hepatitis c diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. 2021."},{"key":"2026032408151697000_16.3.e114119.3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"2026032408151697000_16.3.e114119.4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S2468-1253(24)00442-4","article-title":"Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis","volume":"10","author":"Artenie","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032408151697000_16.3.e114119.5","unstructured":"Geneva, Global HIV HaSPH, Health Product Policy and Standards (HPS) . Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. 2016."},{"key":"2026032408151697000_16.3.e114119.6","unstructured":"Geneva: World Health Organization . Global health sector strategies on, respectively, hiv, viral hepatitis and sexually transmitted infections for the period 2022-2030. 2022."},{"key":"2026032408151697000_16.3.e114119.7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14779"},{"key":"2026032408151697000_16.3.e114119.8","doi-asserted-by":"crossref","first-page":"e1885","DOI":"10.1016\/S2214-109X(23)00461-8","article-title":"Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review","volume":"11","author":"Hajarizadeh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026032408151697000_16.3.e114119.9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S2468-1253(20)30010-8","article-title":"Global hepatitis C elimination: an investment framework","volume":"5","author":"Pedrana","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032408151697000_16.3.e114119.10","unstructured":"Clinton Health Access Initiative, Inc . HCV market intellegence report. 2023."},{"key":"2026032408151697000_16.3.e114119.11","unstructured":"HCV market intelligence report. 2023."},{"key":"2026032408151697000_16.3.e114119.12","unstructured":"World Health Organization . Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva: World Health Organization, Global HIV HaSPH, Guidelines Review Committee. 2022."},{"key":"2026032408151697000_16.3.e114119.13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S2468-1253(23)00335-7","article-title":"Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions","volume":"9","author":"Marshall","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032408151697000_16.3.e114119.14","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2017.1400385"},{"key":"2026032408151697000_16.3.e114119.15","doi-asserted-by":"crossref","first-page":"102633","DOI":"10.1016\/j.drugpo.2019.102633","article-title":"A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment","volume":"76","author":"Palmer","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2026032408151697000_16.3.e114119.16","doi-asserted-by":"crossref","first-page":"101810","DOI":"10.1016\/j.eclinm.2022.101810","article-title":"Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019","volume":"56","author":"van Santen","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026032408151697000_16.3.e114119.17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1111\/liv.14983","article-title":"Outcomes of the CT2 study: A \u201cone-stop-shop\u201d for community-based hepatitis C testing and treatment in Yangon, Myanmar","volume":"41","author":"Draper","year":"2021","journal-title":"Liver Int"},{"key":"2026032408151697000_16.3.e114119.18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jvh.13268","article-title":"A same day \u201ctest and treat\u201d model for chronic HCV and HBV infection: Results from two community-based pilot studies in Egypt","volume":"27","author":"Shiha","year":"2020","journal-title":"J Viral Hepat"},{"key":"2026032408151697000_16.3.e114119.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-023-00780-3","article-title":"Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs","volume":"20","author":"Hassan","year":"2023","journal-title":"Harm Reduct J"},{"key":"2026032408151697000_16.3.e114119.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-024-01001-1","article-title":"Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness","volume":"21","author":"Rajkumar","year":"2024","journal-title":"Harm Reduct J"},{"key":"2026032408151697000_16.3.e114119.21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737159.2023.2292645","article-title":"We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?","volume":"24","author":"Grebely","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"key":"2026032408151697000_16.3.e114119.22","doi-asserted-by":"crossref","first-page":"104317","DOI":"10.1016\/j.drugpo.2024.104317","article-title":"Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility","volume":"125","author":"MacIsaac","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2026032408151697000_16.3.e114119.23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.cgh.2020.07.058","article-title":"Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA","volume":"19","author":"Smookler","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032408151697000_16.3.e114119.24","unstructured":"WHO . Prequalification of in vitro diagnostics public report. 2017."},{"key":"2026032408151697000_16.3.e114119.25","unstructured":"World Bank Group . Armenia. 2023. Available: https:\/\/data.worldbank.org\/country\/armenia"},{"key":"2026032408151697000_16.3.e114119.26","doi-asserted-by":"crossref","DOI":"10.3390\/v16091446","article-title":"Seroprevalence of Hepatitis C Virus and Factors Associated with It in Armenia, 2021","volume":"16","author":"Demirchyan","year":"2024","journal-title":"Viruses"},{"key":"2026032408151697000_16.3.e114119.27","unstructured":"Integrated bio-behavioral surveillance surveys and key population size estimations among people eho inject drugs, female sex workers, men who have sex with men, and transgender persons. Armenia. 2021."},{"key":"2026032408151697000_16.3.e114119.28","unstructured":"The 2021-2026 action plan of the government of the republic of armenia. In: Armenia GotRo, editor. Yerevan. 2021."},{"key":"2026032408151697000_16.3.e114119.29","unstructured":"On approval of the program for the prevention and control of viral hepatitis for 2023-2026 and the list of measures. In: Armenia MoHotRo, editor. Yerevan Minisrty of Health of the Republic of Armeina; 2022."},{"key":"2026032408151697000_16.3.e114119.30","unstructured":"Armenia MoHotRo . On the approval of clinical guidelines for the management of hepatitis C. In: Health Mo, editor. Armenia. 2025."},{"key":"2026032408151697000_16.3.e114119.31","unstructured":"World Bank Group . Georgia. 2023. Available: https:\/\/www.worldbank.org\/en\/country\/georgia\/overview"},{"key":"2026032408151697000_16.3.e114119.32","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiad064","article-title":"Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021","volume":"228","author":"Gamkrelidze","year":"2023","journal-title":"J Infect Dis"},{"key":"2026032408151697000_16.3.e114119.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4741-5","article-title":"Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia","volume":"20","author":"Tsertsvadze","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2026032408151697000_16.3.e114119.34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.15585\/mmwr.mm7330a1","article-title":"Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024","volume":"73","author":"Tohme","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026032408151697000_16.3.e114119.35","unstructured":"Population size estimate of people who inject drugs in Georgia. Tbilisi, Georgia. 2022."},{"key":"2026032408151697000_16.3.e114119.36","unstructured":"World Bank Group . Tanzania. 2023. Available: https:\/\/data.worldbank.org\/country\/tanzania"},{"key":"2026032408151697000_16.3.e114119.37","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/jvh.12966","article-title":"The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania","volume":"25","author":"Mohamed","year":"2018","journal-title":"J Viral Hepat"},{"key":"2026032408151697000_16.3.e114119.38","unstructured":"Nyandindi C , ed. HIV serostatus, hepatitis C and depression among injection drug users in kinondoni municipality, Dar es Salaam, Tanzania. 2011."},{"key":"2026032408151697000_16.3.e114119.39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugpo.2017.05.043","article-title":"Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania","volume":"45","author":"Lambdin","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2026032408151697000_16.3.e114119.40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugpo.2012.08.005","article-title":"An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011","volume":"24","author":"Bowring","year":"2013","journal-title":"Int J Drug Policy"},{"key":"2026032408151697000_16.3.e114119.41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/jvh.13073","article-title":"High prevalence and poor linkage to care of transfusion-transmitted infections among blood donors in Dar-es-Salaam, Tanzania","volume":"26","author":"Mohamed","year":"2019","journal-title":"J Viral Hepat"},{"key":"2026032408151697000_16.3.e114119.42","unstructured":"NACP . Consensus estimates on key population size and HIV prevalence in Tanzania. 2014."},{"key":"2026032408151697000_16.3.e114119.43","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s10461-013-0517-x","article-title":"Estimating the number of people who inject drugs, female sex workers, and men who have sex with men, Unguja Island, Zanzibar: results and synthesis of multiple methods","volume":"18 Suppl 1","author":"Khalid","year":"2014","journal-title":"AIDS Behav"},{"key":"2026032408151697000_16.3.e114119.44","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25817","article-title":"Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania","volume":"24","author":"Fraser","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2026032408151697000_16.3.e114119.45","unstructured":"National Strategic Plan for the Control of Viral Hepatitis 2018\/19-2022\/23. In: Ministry of health Cd, Gender, Elderly and Children, editor: Unted Republic of Tanznaia. 2018."},{"key":"2026032408151697000_16.3.e114119.46","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated Consolidated Framework for Implementation Research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci"},{"key":"2026032408151697000_16.3.e114119.47","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-020-0977-0","article-title":"Evaluating and optimizing the consolidated framework for implementation research (CFIR) for use in low- and middle-income countries: a systematic review","volume":"15","author":"Means","year":"2020","journal-title":"Implement Sci"},{"key":"2026032408151697000_16.3.e114119.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"2026032408151697000_16.3.e114119.49","unstructured":"Sofosbuvir-Velpatasvir (Epclusa) Hepatitis C Online. 2022. Available: https:\/\/www.hepatitisc.uw.edu\/page\/treatment\/drugs\/epclusa\/prescribing-information#jump-34073-7"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-114119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:30:15Z","timestamp":1774366215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-114119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,24]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-114119"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-114119","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}